Opendata, web and dolomites

PICSOHF SIGNED

PICSOHF, A minimally invasive cardiac intervention medical device to regenerate a damaged heart and extend the life of patients with Heart Failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PICSOHF project word cloud

Explore the words cloud of the PICSOHF project. It provides you a very rough idea of what is the project "PICSOHF" about.

regain    technological    continuous    22    treating    survival    scientific    clinical    follow    strategic    proprietary    expectations    efficacy    expectancy    minutes    healthcare    patient    treatments    patients    acute    regeneration    quality    consists    demonstrated    full    once    medium    device    therapies    hospitalisations    catheter    intervention    significantly    66m    progressive    launch    regenerate    temporarily    ed    elevates    hf    damaged    improvements    partial    feedback    attack    changed    controls    proof    discredited    innate    chronic    worldwide    despite    impoverished    sustainability    patented    software    million    breakthrough    stop    profits    reference    threatens    function    greatest    percutaneous    pressure    burden    prognosis    treatment    cellular    people    co    re    frequent    picsohf    life    changing    met    reactivating    commercial    tested    last    market    right    pattern    live    therapy    solutions    europe    picso    cardiac    versus    miracor    unable    hope    recovery    26    national    regenerative    morbidities    biomarkers    clinically    heart    tissue    myocardial    veins   

Project "PICSOHF" data sheet

The following table provides information about the project.

Coordinator
MIRACOR MEDICAL 

Organization address
address: RUE DE BRUXELLES 174, E40 BUSINESS
city: AWANS
postcode: 4340
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MIRACOR MEDICAL BE (AWANS) coordinator 50˙000.00

Map

 Project objective

Worldwide 26 million people live with HF (Heart Failure) which is a major burden, not only for the patient, but one that also threatens the sustainability of national healthcare systems. Despite advances in treatment solutions over the last 30 years, improvements have not met the expectations for cardiac recovery and prognosis following heart attack. Current treatments are only partial solutions as they cannot regenerate the damaged heart tissue, and are thus unable to stop the progressive loss of heart function, low short- and medium-term life expectancy, and impoverished quality of life due to co-morbidities and/or frequent and continuous re-hospitalisations. Regenerative concepts, such as cellular therapies to regain cardiac function, once of the greatest hope for heart failure patients, have been recently discredited as they have been unable to show scientific proof of efficacy. Miracor, developed and clinically tested PiCSO, a breakthrough cardiac intervention triggering myocardial regeneration. Our therapy consists of a percutaneous right heart catheter intervention using proprietary software for feedback control that temporarily elevates the pressure in cardiac veins reactivating innate regeneration pathways. We have tested PiCSO in chronic HF patients (8 patients versus 22 controls) and demonstrated that 30 minutes of intervention changed the pattern of regenerative biomarkers in cardiac veins that resulted in significantly improved survival at 10 years follow up. Our patented technology (PiCSOHF ) is changing the market in HF, as no similar device is currently available. Our strategic goal is to become Europe´s leading reference in treating HF. After full technological, clinical and commercial development, PICSOHF profits will increase by €66M within 5 years after commercial launch.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PICSOHF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PICSOHF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More  

EVERCAM (2020)

Intelligent Vision System for Improved Communication and Higher Productivity in Construction

Read More